Human Relaxin-2 Dosage & Reconstitution Guide
Research and educational use only — not medical advice, and not for human consumption. The figures below are summarized from public sources, product labeling, and community reports, and are not a prescription or a substitute for a qualified clinician.
Dosing guide
| Level | Dose | Notes |
|---|---|---|
| Clinical infusion | 30 mcg | 30 µg/kg/day continuous IV, ~48 h (hospital setting) |
Timing & cycling
The studied route is a continuous IV infusion over ~48 hours in a hospital (the acute-heart-failure trials). There is no subcutaneous home protocol.
Cycle length. 48-hour infusion in the trial setting; not a repeating self-run cycle.
Storage & handling
Keep the lyophilized (unmixed) vial refrigerated at 2–8 °C (36–46 °F) in a dry, dark place — it tolerates short periods at room temperature during shipping. Once reconstituted, store it at 2–8 °C, never frozen, and use it within about 2–4 weeks (sooner if the solution turns cloudy or discolored). Swab the stopper before every draw and use a fresh needle each time.
Key points
- Serelaxin (recombinant relaxin-2) was trialed for acute heart failure; the headline efficacy trial did not meet its primary endpoint.
- Nothing about a weight-scaled 48-hour IV infusion translates to at-home use — this page documents the real protocol, which is inpatient only.
What to monitor
Blood pressure and renal/hepatic markers — this was studied under continuous hospital monitoring for a reason.
Legal & prescription status
No legal prescription exists. It is an unapproved research chemical, sold only for laboratory research and labelled 'not for human consumption.' It is not FDA-approved for any human use.
References
This guide is for research and educational purposes only. It is not medical advice and does not describe a product approved for human use. Always consult a qualified healthcare professional before considering any peptide protocol.